EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC-ND 4.0

Navigating the peginterferon Alfa-2a shortage: practical guidance on transitioning patients to ropeginterferon alfa-2b

Ruben Mesa, Abdulraheem Yacoub, Tsewang Tashi, Wanxing Chai-Ho, Chang Ho Yoon, John Mascarenhas

Annals of Hematology · 2025-04 · 104 (4) · 2571-2573

DOI: 10.1007/s00277-025-06331-z ↗

Kurz gefasst

Leserbrief in der Zeitschrift Annals of Hematology, online erschienen am 03.04.2025. Verfasst von Ruben Mesa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Levine Cancer Institute, 1021 Morehead Medical Drive, Suite 3100, Charlotte, NC, 28204, USA. rmesa@wakehealth.edu. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

weeks, adjusting for hematologic response and tolerability.Those on lower peg-IFN doses (45-90 µg/week) may begin on 200-250 µg every two weeks.If disease control proves challenging, starting at, e.g., 350 µg with possible escalation to 500 µg every two weeks can be considered.Whichever starting dose is chosen, close monitoring and dose adjustments are essential to maintain efficacy while minimizing toxicity.Close follow-up is crucial, particularly in the first 3-4 months post-transition:• Monthly visits to assess MPN-related symptoms, CBC, liver function tests (LFTs), thyroid function (TSH, free T4), and potential psychiatric, autoimmune, or ophthalmologic side effects.Where there are no pre-existing psychiatric or autoimmune conditions, we would recommend screening through detailed history and physical examination before undertaking any targeted tests.In patients with known or uncontrolled psychological disorders, involvement of a psychologist or psychiatrist before transitioning to ropeg-IFN may be warranted. Dear Editor,We write to highlight the critical shortage of peginterferon alfa-2a (peg-IFN), as confirmed by the FDA [1], which has impacted many patients with myeloproliferative neoplasms (MPNs).Those relying on peg-IFN for long-term disease control in polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) face supply disruptions that can compromise disease stability and overall health.Ropeginterferon alfa-2b (ropeg-IFN) is a viable alternative.It is the only FDA-approved interferon for PV and is considered first-line therapy as per the January 2025 NCCN Guidelines [2].Though not yet approved for ET or MF, off-label use may be justified in situations where no other options exist.Our group has accumulated experience in transitioning patients from peg-IFN to ropeg-IFN due to historic insurance issues and clinical trial participation, allowing us to propose practical strategies for safe conversion.A best-practice approach to dose equivalence, based on collective experience and real-world data, is pragmatic given that no formal head-to-head dosing trials exist.[3-5]For patients previously on peg-IFN 135-180 µg weekly, we typically initiate ropeg-IFN at 250-350 µg every two

Autor:innen und Institutionen

  • Levine Cancer Institute, 1021 Morehead Medical Drive, Suite 3100, Charlotte, NC, 28204, USA. rmesa@wakehealth.edu.
  • Wake Forest University School of Medicine, 475 Vine Street, Winston-Salem, NC, 27101, USA. rmesa@wakehealth.edu.
  • Atrium Health Levine Cancer Institute, 1021 Morehead Medical Drive, Charlotte, NC, 28204, USA. rmesa@wakehealth.edu.
  • The University of Kansas Medical Center, 2060 W 39th Ave, Kansas City, KS, 66103, USA.
  • The University of Utah Huntsman Cancer Institute, 2000 Cir of Hope Dr, Salt Lake City, UT, 84112, USA.
  • Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.

Zitieren

APA

Mesa, R., Yacoub, A., Tashi, T., Chai-Ho, W., Yoon, C. H., & Mascarenhas, J. (2025). Navigating the peginterferon Alfa-2a shortage: practical guidance on transitioning patients to ropeginterferon alfa-2b. Annals of Hematology, 104(4), 2571-2573. https://doi.org/10.1007/s00277-025-06331-z

Vancouver

Mesa R, Yacoub A, Tashi T, Chai-Ho W, Yoon CH, Mascarenhas J. Navigating the peginterferon Alfa-2a shortage: practical guidance on transitioning patients to ropeginterferon alfa-2b. Annals of Hematology. 2025;104(4):2571-2573. doi:10.1007/s00277-025-06331-z

BibTeX
@article{Mesa2025,
  author = {Mesa, Ruben and Yacoub, Abdulraheem and Tashi, Tsewang and Chai-Ho, Wanxing and Yoon, Chang Ho and Mascarenhas, John},
  title = {Navigating the peginterferon Alfa-2a shortage: practical guidance on transitioning patients to ropeginterferon alfa-2b},
  journal = {Annals of Hematology},
  year = {2025},
  volume = {104},
  number = {4},
  pages = {2571--2573},
  doi = {10.1007/s00277-025-06331-z}
}
Kostenlos starten →